At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
dasatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating dasatinib and laboratory biomarker analysis for Recurrent Skin Cancer and 3 related conditions. Completed, enrolled 7 participants across 3 sites.
Detailed Summary
This phase II trial is studying how well dasatinib works in treating patients with unresectable or metastatic squamous cell skin cancer or RAI Stage 0-I chronic lymphocytic leukemia. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedNov 2007
Primary CompletionApr 2012
Study CompletionOct 2014
TodayJul 2026
First PostedNov 26, 2007
Enrollment StartNov 1, 2007
Primary CompletionApr 1, 2012
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 18.6 years ago
Interventions
dasatinibdrug
Given PO
laboratory biomarker analysisother
Correlative studies